TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02382666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rolapitant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rolapitant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rolapitant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rolapitant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rolapitant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rolapitant
Study: NCT02532335

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Obeticholic acid
Description: active drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Obeticholic acid
Description: active drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Obeticholic acid
Description: active drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Obeticholic acid
Description: active drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Obeticholic acid placebo
Description: matching placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Obeticholic acid placebo
Description: matching placebo
Study: NCT01698970

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1-Freeze-dried Probiotics provided in capsule (150 mg) containing 1,0x10E10 colony forming unit per capsule (test)
Description: 1- 6 test products/day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 2- excipients (150 mg) in capsule (control)
Description: 2- 6 control poducts/day
Study: NCT05385380

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safe motherhood Promotion
Description: Interventions included the training of community members, who subsequently led participatory educational sessions on safe motherhood topics with pregnant females. The project staff identified 2 community health workers and 15 female volunteers from each kebele cluster and trained them as research implementers. The implementers received 2 days of training led by the project team. The project staff and research implementers conducted safe-motherhood training comprising 2 h of information presentations and discussions with pregnant females in the intervention clusters. In addition to the pregnant-female intervention strategy, we also conducted a four-day training programme on clinical skills for local maternal and child healthcare providers in the study area. MWH intervention was also implemented in the intervention group, including upgrades to existing MWH services per national guidelines to standardize services and create a homelike environment for pregnant females.
Study: NCT01173965

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MEA
Description: Microwave endometrial ablation device
Study: NCT03418259

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KCS Medical Device
Description: Patient treated 6 times with the Active KCS Medical Device during 2 weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: KCS Medical Device
Description: Patient treated 6 times with the Inactive KCS Medical Device during 2 weeks.
Study: NCT03307928

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary Exercise Test Protocol
Description: The CPET was performed in a cycle ergometer with electromagnetic braking using an Inbrasport (Inbrasport, Porto Alegre, Rio Grande do Sul, Brazil). Following a 5-min warm-up against no resistance (0 W), the work rate was increased using a ramp protocol (5-10 W.min-1) until maximum exercise tolerance. Verbal encouragements were given during the CPET to ensure maximal effort.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary Exercise Test Protocol
Description: The CPET was performed in a cycle ergometer with electromagnetic braking using an Inbrasport (Inbrasport, Porto Alegre, Rio Grande do Sul, Brazil). Following a 5-min warm-up against no resistance (0 W), the work rate was increased using a ramp protocol (5-10 W.min-1) until maximum exercise tolerance. Verbal encouragements were given during the CPET to ensure maximal effort.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Polysomnography Assessment
Description: The polysomnography assessment was carried out during an entire night of sleep in the participant's residence with no use of sedatives. The variables were monitored by an Embletta portable respiratory monitor (Embla, Embletta® Gold, EUA), previously validated, and in agreement with manufacturer's instructions. The Embletta monitor was capable to monitor continuously the pulse oximetry, to detect respiratory efforts, to measure the airflow, and to record snoring episodes. Additionally, HR was continually measured by the analysis of pulse waves by oximetry. Finally, brain and muscle activities were monitored by electrodes and oxygen desaturation (O2D) was defined as the amount of reduction in O2S in 4%/h.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Polysomnography Assessment
Description: The polysomnography assessment was carried out during an entire night of sleep in the participant's residence with no use of sedatives. The variables were monitored by an Embletta portable respiratory monitor (Embla, Embletta® Gold, EUA), previously validated, and in agreement with manufacturer's instructions. The Embletta monitor was capable to monitor continuously the pulse oximetry, to detect respiratory efforts, to measure the airflow, and to record snoring episodes. Additionally, HR was continually measured by the analysis of pulse waves by oximetry. Finally, brain and muscle activities were monitored by electrodes and oxygen desaturation (O2D) was defined as the amount of reduction in O2S in 4%/h.
Study: NCT02511925

Intervention type: OTHER
Intervention: Weekly poster of unit performance
Description: Weekly feedback is provided to the ICU about current levels of hand hygiene compliance amongst doctors, nurses, and allied healthcare professionals

Intervention type: OTHER
Intervention: Weekly poster of unit performance
Description: Weekly feedback is provided to the ICU about current levels of hand hygiene compliance amongst doctors, nurses, and allied healthcare professionals

Intervention type: OTHER
Intervention: Weekly poster of unit performance
Description: Weekly feedback is provided to the ICU about current levels of hand hygiene compliance amongst doctors, nurses, and allied healthcare professionals

Intervention type: OTHER
Intervention: Daily email of personal feedback
Description: Healthcare workers receive private and personal feedback via email regarding their individual performance benchmarked against the average performance for their professional grouping.

Intervention type: OTHER
Intervention: Daily email of personal feedback
Description: Healthcare workers receive private and personal feedback via email regarding their individual performance benchmarked against the average performance for their professional grouping.

Intervention type: OTHER
Intervention: Daily email of personal feedback
Description: Healthcare workers receive private and personal feedback via email regarding their individual performance benchmarked against the average performance for their professional grouping.

Intervention type: OTHER
Intervention: Active reminder from badge
Description: The badge the healthcare worker is wearing vibrates if opportunities to perform hand hygiene are missed

Intervention type: OTHER
Intervention: Active reminder from badge
Description: The badge the healthcare worker is wearing vibrates if opportunities to perform hand hygiene are missed
Study: NCT04001803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAB LA+RPV LA
Description: Subjects will receive one tablet of CAB 30 milligram(mg) + RPV 25 mg once daily from Day 1 for 1 month. During month 1, subjects will receive 600 mg of CAB LA injection+ 900 mg of RPV LA injection. Following Month 1, subjects will receive 400mg of CAB LA + 600mg of RPV LA at each subsequent injection.
Study: NCT02377609

Intervention type: DRUG
Intervention: Tacrolimus
Description: oral
Study: NCT03899857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be added to standard of care
Study: NCT02056418

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: enteral nutrition
Description: enteral nutrition only (Nutrison Fibre, 20-30kcal/kg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroid
Description: corticosteroid(equal dose to prednisone 0.75mg/kg/day,4 weeks)
Study: NCT05292261

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recreational team handball
Description: Two to three weekly sessions of recreational team handball training for 36 weeks. Each 60-min session started with a standardised warm-up (including running, coordination, strength, flexibility, and balance exercises) followed by three 15-min periods of recreational team handball matches, interspersed by 2-min breaks, played as small-sided games (4v4, 5v5 or 6v6). The training sessions were performed on an indoor team handball court (40x20 m) adjusted to result in 34-36 m2 per player. During the matches, the participants rotated positions every 3 min in a random order, including the goalkeeper and no exclusions or substitutions were applied.
Study: NCT01173965

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Novasure
Description: Bipolar impedence control system
Study: NCT01582230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Patient will receive vildagliptin 50mg twice daily (bid) in addition to their stable dose of insulin with or without metformin for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patient will receive matching placebo to vildagliptin in addition to their stable dose of insulin with or without metformin for 24 weeks
Study: NCT02297490

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment is identical to the active treatment schedule. The placebo-preparation used is identical to the active solution but without any allergen substance in it.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allergovit 6-grasses
Description: Immunotherapy will be performed for approx. 5 months. 7 injections will be administered at weekly intervals to reach the maintenance dose. However, dosing must be individualised.
Study: NCT04464291

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Detection of Streptococcus pneumoniae strains
Description: There will be detection of Streptococcus pneumoniae, serotype identification, susceptibility tests for penicillin, erythromycin, azithromycin, tetracycline, ciprofloxacin, levofloxacin, moxifloxacin and vancomycin
Study: NCT03521869

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compression bandage
Description: Compression bandage placed after total knee replacement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gauze dressing
Description: standard of care gauze dressing placed after total knee replacement
Study: NCT00327717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Description: Patients entered a 4-week titration period, during which zonisamide dosing began at 100 mg/day for the first 2 weeks, increased to 200 mg/day for the 3rd week, and to 300 mg/day for the 4th week, reaching 300 mg/d at the end of the titration period. 300 mg/d was the target dose in the titration period and must be reached. Dose increment was continued to 400 mg/d if this was tolerated by the patient.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in placebo group were titrated with placebo in the same way as in zonisamide group.
Study: NCT01158261

Intervention type: BIOLOGICAL
Intervention: EVICEL ™ Fibrin Sealant (Human)
Description: Commercial Evicel
Study: NCT04004312

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Shorter radiation therapy means that a higher dose will be offered. To limit side effects of exposure to a high dose, a medical device protecting the rectum will be used. The medical device to be used is called SpaceOAR hydrogel (device). The SpaceOAR hydrogel creates space between the rectum and the prostate, making it much less likely that the rectum is exposed to radiation. It is injected into place prior to the start of radiation treatment using a needle. Patients may be awake or asleep under local anesthesia for the procedure. SpaceOAR hydrogel is not painful, it remains stable during radiation therapy and then is gradually absorbed by the body over the course of approximately six months, once radiation therapy has been completed.
Study: NCT01945346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX167700
Description: Oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule
Study: NCT04884347

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alline proMEN
Description: 1 tablet per day intake during the meal with a glass of water. Treatment duration: 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet per day intake during the meal with a glass of water. Treatment duration: 3 months
Study: NCT01417975

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Exercise Group
Description: Participants will be required to walk briskly (equivalent to moderate intensity) on a treadmill for 10 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Passive Sitting Group
Description: Participants will be required to sit passively on a chair for 10 minutes.
Study: NCT03586050

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microwave ablation
Description: All patients will receive microwave ablation using the NeuWave Microwave Ablation System and Accessories
Study: NCT00537186

Intervention type: DRUG
Group type: OTHER
Intervention: Iron oligosaccharide
Study: NCT01820897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin-Trometamol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfamethoxazole trimethoprim
Study: NCT00379899

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cinacalcet
Description: Low dose vitamin D with cinacalcet
Study: NCT02404610

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Moderate Procedural Sedation with a sedative medication.
Description: procedural sedation with a target sedation depth of moderate. Moderate sedation is not a drug specific intervention, it is achieved with the use of a sedative or a combination of sedations and opioids.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Procedural Sedation with a sedative medication.
Description: procedural sedation with a target sedation depth of deep. Deep sedation is not a drug specific intervention, it is achieved with the use of a sedative or a combination of sedations and opioids.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Study: NCT02898233

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Deprexis
Description: Deprexis is an experimental internet-based treatment program for depression created by Gaia (Hamburg, Germany).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Deprexis
Description: Deprexis is an experimental internet-based treatment program for depression created by Gaia (Hamburg, Germany).

Intervention type: OTHER
Group type: OTHER
Intervention: Deprexis
Description: Deprexis is an experimental internet-based treatment program for depression created by Gaia (Hamburg, Germany).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active low-level light therapy
Description: Administration of LLLT consists of applying light of a specific wavelength (1064 nanometers) that intersects with the absorption spectrum of cytochrome oxidase, using a laser diode, the high density laser (HD laser; Cell Gen Therapeutics, LLC). Active LLLT includes 4 days, once per week for 4 weeks, during which LLLT is applied to two alternating positions on the participant's right forehead for 8 minutes total.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham low-level light therapy
Description: Administration of LLLT consists of applying light of a specific wavelength (1064 nanometers) that intersects with the absorption spectrum of cytochrome oxidase, using a laser diode, the high density laser (HD laser; Cell Gen Therapeutics, LLC). Sham LLLT includes 4 days, once per week for 4 weeks, during which sham LLLT (5 seconds active, 55 seconds sham) is applied to two alternating positions on the participant's right forehead for 8 minutes total.
Study: NCT01715701

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paravertebral nerve blockade
Description: Paravertebral nerve blockade using ropivacaine, intercostal nerve blockade using saline and PCA using hydromorphone or morphine.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intercostal nerve blockade
Description: Intercostal nerve blockade using ropivacaine, simulated paravertebral nerve blockade and PCA using hydromorphone or morphine.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient Controlled Analgesia
Description: Simulated paravertebral nerve blockade, intercostal nerve blockade using saline and PCA using hydromorphone or morphine.
Study: NCT03200210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat tablets would be given to patients at dose of 20mg/d, once a day, and dose would be adjusted according to serum uric acid at specific visits.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pills manufactured to mimic Febuxostat tablets
Study: NCT02923999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2G12 Dose Cohort 1
Description: single dose of intravenous infusion: 0.125g of the P2G12 human monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2G12 Dose Cohort 2
Description: single dose of intravenous infusion: 0.25g of the P2G12 human monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2G12 Dose Cohort 3
Description: single dose of intravenous infusion: 0.5g of the P2G12 human monoclonal antibody
Study: NCT01340755

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transanal endoscopic surgery
Description: Laparoscopy-assisted transanal endoscopic rectosigmoid resection
Study: NCT03838939

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Therapeutic education
Description: Individual and group therapeutic education sessions will consist of :~* acquisition by patient of self-care skills such as performing subcutaneous injection,~* acquisition by patient of safety skills such as identifying symptoms that should lead to consult general practitioner, and stop treatment ...

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic education
Description: Individual and group therapeutic education sessions will consist of :~* acquisition by patient of self-care skills such as performing subcutaneous injection,~* acquisition by patient of safety skills such as identifying symptoms that should lead to consult general practitioner, and stop treatment ...
Study: NCT02835859

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary: saccharin
Description: Assess the glycemic and hormonal responses to an oral glucose load preceded by an oral solution of NCASs (saccharin).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Estimate glucose absorptions
Description: Indirectly estimate the rate of glucose absorption and gastric emptying by using 3-O-methyglucose (3-OMG) and acetaminophen, respectively.
Study: NCT01387178

Intervention type: DRUG
Intervention: fluticasone propionate/salmeterol 250µg/50µg (FSC)
Description: Patient records with evidence of COPD and prescription claims for FSC

Intervention type: DRUG
Intervention: fluticasone propionate/salmeterol 250µg/50µg (FSC)
Description: Patient records with evidence of COPD and prescription claims for FSC

Intervention type: DRUG
Intervention: tiotropium bromide (TIO)
Description: Patient records with evidence of COPD and prescription claims for TIO
Study: NCT01229605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and docetaxel
Description: Cyclophosphamide and docetaxel every 3 weeks as neoadjuvant chemotherapy
Study: NCT01711853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate
Description: Dabigatran Etexilate 75mg twice daily
Study: NCT03117491

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GGNB injections
Description: The patients received two GGNB injections of 1.8 mL 2% lidocaine with 1:100,000 epinephrine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IANB injections
Description: The patients received two IANB injections of 1.8 mL 2% lidocaine with 1:100,000 epinephrine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GGNB + IANB injections
Description: The patients received one GGNB injection plus one IANB injection of 1.8 mL 2% lidocaine with 1:100,000 epinephrine
Study: NCT01387191

Intervention type: DRUG
Intervention: Epoprostenol
Study: NCT03722225

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate loading and high intermittent carbohydrate intake during physical exercise
Description: The intervention consisted of carbohydrate loading prior to and intermittent high carbohydrate intake during PE and a proactive use of Real-Time Continuous Glucose Monitoring (rtCGM) to achieve and maintain glucose control
Study: NCT00476164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 2 doses of 1g 14 days apart
Study: NCT01387178

Intervention type: DRUG
Intervention: tiotropium bromide (TIO)
Description: Patient records with evidence of COPD and prescription claims for TIO
Study: NCT02111174

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scrambler Therapy
Study: NCT00476164

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control arm
Description: Continue of optimised oral immunosuppression
Study: NCT02402153

Intervention type: DEVICE
Group type: OTHER
Intervention: Hyposafe device
Description: Subcutaneous EEG recorder for EEG measurements
Study: NCT02498782

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fexinidazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fexinidazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fexinidazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fexinidazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fexinidazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fexinidazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo